Global Leading Market Research Publisher QYResearch announces the release of its latest report “AI Plaque Analysis Solution – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. The global burden of cardiovascular disease, a leading cause of mortality, is driving an urgent need for more precise, early-stage diagnostic tools. Traditional imaging analysis, often reliant on subjective visual assessment, is being revolutionized by Artificial Intelligence (AI). According to the latest comprehensive market analysis, the global market for AI Plaque Analysis Solutions is poised for significant growth, projected to expand from an estimated US2,909millionin2025toUS7,917 million by 2032, achieving a robust Compound Annual Growth Rate (CAGR) of 15.6%. This growth is fueled by the convergence of advanced deep learning algorithms, the proliferation of high-resolution medical imaging, and the clinical imperative to stratify patient risk more accurately for conditions like coronary artery disease and stroke.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
/reports/6095940/ai-plaque-analysis-solution
Market Definition and Clinical Imperative
An AI Plaque Analysis Solution is a sophisticated software platform that integrates deep learning with medical image processing to automatically identify, characterize, and quantify atherosclerotic plaques within vascular imaging studies, such as Coronary Computed Tomography Angiography (CCTA) and Carotid Ultrasound. These solutions move beyond simple detection to provide granular data on plaque morphology, volume, and composition (e.g., calcified vs. lipid-rich “vulnerable” plaque). This quantitative analysis delivers objective, reproducible metrics that empower clinicians to detect subclinical atherosclerosis earlier, assess stroke and heart attack risk with greater precision, and personalize treatment strategies, ultimately aiming to improve patient outcomes and healthcare efficiency.
Competitive Landscape and Market Segmentation
The competitive arena features a mix of specialized medical imaging AI pioneers, established cardiovascular diagnostics companies, and imaging hardware manufacturers expanding into software. Key players profiled in the report include Medis Medical Imaging, Cleerly, Heartflow, Artrya, Spimed-AI, Caristo Diagnostics, RSIP Vision, Circle, RadNet, Brainomix, RapidAI, Elucid, and leading Asia-Pacific firms like Shanghai United Imaging and Beijing Infervision Technology. The top five players held a significant portion of 2025 revenue, indicating a market where regulatory clearance, clinical validation, and integration with hospital PACS systems are key competitive barriers.
Market Segmentation Analysis:
By Type (Analysis Focus):
Coronary Plaque Analysis: The dominant segment, driven by the widespread adoption of CCTA for chest pain evaluation and preventive cardiology. Solutions here quantify coronary plaque burden, a critical biomarker for guiding statin therapy and invasive interventions.
Stroke Plaque Analysis: A high-growth segment focused on analyzing carotid artery plaque to assess stroke risk. The ability to characterize plaque instability is crucial for decisions regarding carotid endarterectomy or stenting.
By Application:
Clinical Application: The primary driver of market growth. Hospitals and imaging centers are adopting these tools to enhance radiology reports, support cardiologists and neurologists in diagnosis, and meet the demand for more quantitative, actionable imaging data.
Medical Research: A vital segment where these solutions are used in pharmaceutical trials to measure drug effects on plaque regression/progression and in large-scale epidemiological studies to understand disease natural history.
Market Dynamics: Drivers, Evidence, and Regulatory Hurdles
The strong 15.6% CAGR is underpinned by clear clinical and economic value propositions, as evidenced by recent developments:
Landmark Clinical Evidence: The publication of several major studies in early 2026, such as the CORONARY-AI trial, demonstrated that AI-quantified plaque characteristics were superior to standard stenosis assessment in predicting future major adverse cardiac events. This level of evidence is accelerating adoption and convincing payers of the technology’s value.
Integration with Preventive Cardiology Paradigms: There is a global shift towards identifying and treating high-risk atherosclerosis beforesymptoms occur. AI plaque analysis is the enabling technology for this paradigm, allowing for population-level screening of at-risk individuals (e.g., diabetics, those with familial hypercholesterolemia) using routine CT scans.
Regulatory Tailwinds and Reimbursement Pathways: The U.S. FDA and EU’s MDR have granted an increasing number of De Novo and CE Mark approvals for AI plaque analysis software as SaMD (Software as a Medical Device). Furthermore, the establishment of new CPT III codes in the U.S. for AI-assisted coronary plaque analysis is a critical step towards creating a sustainable reimbursement model, a factor highlighted as a significant growth catalyst in the report.
Technical and Adoption Challenges:
Despite the promise, challenges remain. Algorithm generalizability across different CT scanner models and imaging protocols is a persistent technical hurdle. Furthermore, integrating these standalone AI solutions into the already complex clinical workflow of a hospital’s radiology department requires seamless PACS/RIS integration and poses a significant operational challenge. The “black box” nature of some complex neural networks also raises concerns about explainability, requiring vendors to provide clear visualizations of the AI’s findings to build trust among clinicians.
Regional Outlook and Strategic Imperatives
North America is the largest market, driven by high healthcare expenditure, a favorable regulatory environment for digital health, and early adoption by leading academic medical centers.
Europe is a strong and growing market, with adoption supported by national health technology assessment bodies beginning to evaluate the cost-effectiveness of these tools.
Asia-Pacific is projected to be the fastest-growing region, fueled by massive patient populations, rising healthcare investments, and the presence of agile technology developers in China, Japan, and South Korea.
Strategic Outlook: The future of the AI Plaque Analysis market lies in the evolution from a quantitative analysis tool to an integrated clinical decision support system. Successful vendors will be those that combine plaque data with genetic, biomarker, and clinical data to provide a holistic cardiovascular risk score. Additionally, the development of therapy guidance features—suggesting optimal medical therapy or the need for revascularization based on plaque characteristics—will represent the next frontier in adding clinical value and securing market leadership.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
